Bisphosphonate-induced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma.
Del Conte
Alessandro
A
Department of Oncology, S. Giuseppe Hospital, Empoli, Italy. alx-delconte@libero.it
Bernardeschi
Paolo
P
La Ferla
Fabio
F
Turrisi
Gina
G
D'Alessandro
Michelina
M
Montagnani
Francesco
F
Fiorentini
Giammaria
G
D000368:Aged; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008439:Maxillary Diseases / Q000139:chemically induced*; D009101:Multiple Myeloma / Q000188:drug therapy*; D009957:Oroantral Fistula / Q000139:chemically induced; D010020:Osteonecrosis / Q000139:chemically induced*; D000077211:Zoledronic Acid
D000900:Anti-Bacterial Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D019980:Amoxicillin-Potassium Clavulanate Combination